Valmisar H - the antagonist of angiotensin II and diuretic, for treatment of arterial hypertension at patients whose pressure of blood is not regulated by monotherapy.

Structure

• active ingredient: valsartan and hydrochlorothiazide;
• 1 tablet contains 80 mg of a valsartan and 12.5 mg of a hydrochlorothiazide;
• other components: microcrystalline cellulose, krospovidon, silicon dioxide colloidal anhydrous, magnesium stearate;
• covering of Opadry Pink 03F84641: gipromelloza, titan dioxine (E 171), polyethyleneglycol, talc, dye ferrous oxide red (E 172), ferrous oxide yellow (E 172);

Contraindication

• Hypersensitivity to components of medicament or other derivatives of sulfonamides.
• Heavy abnormal liver functions, cirrhosis and cholestasia.
• Anury, heavy renal failures (clearance of creatinine of 30 ml/min.).
• Refractory hypopotassemia, hyponatremia, hypercalcemia, symptomatic hyperuricemia.
• Simultaneous use of the antagonists of receptors of angiotensin (ARA), including valsartan, or inhibitors of angiotensin-converting enzyme (APF) with aliskireny to patients with diabetes or a renal failure (SKF <60 ml/min. / 1.73 sq.m).
• Pregnant women or the planning women.

Side reactions

Metabolism and disorders of food – infrequently – dehydration.

from nervous system – it is very rare – dizziness

from organs of sight – infrequently – blurring of sight.

from organs of hearing and balance – infrequently – vertigo.

from the vascular system – hypotension.

from respiratory organs, the thorax and mediastinum – is unknown a fluid lungs.

from a digestive tract – infrequently diarrhea.

from a liver and biliary tract – does not know increase in indicators of function of a liver, including increase in level of bilirubin in blood serum.

Route of administration

Valsartan and a hydrochlorothiazide can be accepted with food or without it, washing down with water.

Recommended dose of a valsartan and a hydrochlorothiazide of 80/12.5 mg or 160/12.5 mg with a film covering a tablet of 1 times a day.

In need of a dose can be adjusted. The clinical answer on valsartan and a hydrochlorothiazide should be estimated after the beginning of therapy. If the ABP remains uncontrollable, the dose can be increased.

Essential antihypertensive effect occurs within 2 weeks

Maximum antihypertensive effect is reached during 2-4 weeks. For some patients 4-8 weeks of treatment can be required. It should be considered at titration of a dose.

Feature of use

Use during pregnancy or feeding by a breast

Medicine should not be applied to pregnant women or women who are going to become pregnant. If during treatment the pregnancy is confirmed by it, its use needs to be stopped and replaced immediately with other medicine allowed for use to pregnant women.

If needs extremely use of drug, feeding by a breast should be stopped.

Valmisar the N is not recommended by

for use to children due to the lack of data on safety and efficiency.

Ability to influence speed of response at control of motor transport or other mechanisms

Research on influence on ability to run motor transport and work with other mechanisms were not carried out by

. It must be kept in mind that at control of motor transport or work with other mechanisms the developing of dizziness or weakness is possible.

Overdose

as a result of overdose can develop the profound arterial hypotension that can lead to oppression of consciousness, vascular collapse and/or shock. Therapeutic actions depend on time of reception and type and weight of symptoms; blood circulation stabilization has paramount value. When developing arterial hypotension the patient has to be in a prone position, it is also necessary to carry out correction of volume of blood. Valsartan it is impossible to bring out of an organism by means of a hemodialysis because of its linking with proteins of plasma, but for removal from a hydrochlorothiazide organism the hemodialysis is effective.

Accompanying use is not recommended to

Lities

Was reported about temporary increase in concentration of lithium in blood serum and toxicity during the accompanying intake of lithium and APF inhibitors and/or tiazid. There is no experience of the accompanying reception of a valsartan and lithium therefore it is recommended to check concentration of lithium in blood serum.

Accompanying use demanding extra care

Other antihypertensive medicaments

Drug can enhance hypotensive effect of other antihypertensive medicaments (such as guanetidin, Methyldopum, vazodilatator, APF inhibitors, blockers of receptors of angiotensin, beta-blockers, blockers of calcium channels).

Presorny amines (for example, noradrenaline, adrenaline)

Probable decrease in reaction to pressor amines. The clinical importance of this effect is authentically unknown and insufficient to exclude their use.

Non-steroidal anti-inflammatory medicaments (NPVP), including selection TsOG-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NPVP.

NPVP can weaken hypotensive effect of both antagonists of angiotensin II, and a hydrochlorothiazide at their accompanying use. Besides, the accompanying use valsartana / a hydrochlorothiazide and NPVP can lead to deterioration in function of kidneys and increase in level of potassium in blood serum. Thus, it is recommended to conduct monitoring of function of kidneys in an initiation of treatment and also to provide to the patient appropriate replenishment of liquid.

Storage conditions

to Store

at a temperature not over 25 With in original packing.

to Store

out of children's reach.